This is a multicenter, category D study designed to test to the efficacy and safety of a new (1-antitrypsin preparation. The Utah site has recruited five subjects, and all of them were evaluated. All participants will continue to receive 60 mg/kg/week of the new preparation for up to two years. Bronchoalveolar lavages were performed on all subjects at enrollment (to establish baseline values), and again a week after the sixth infusion of (1-PI or control product. Data analyses are currently being done by the industrial sponsor. No reports are yet available, although the drug does appear to be safe.
Showing the most recent 10 out of 535 publications